Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib

Abstract

Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early‐onset interstitial pneumonitis occurred within two days.

Keywords

• Crizotinib
• early‐onset interstitial pneumonitis
• NSCLC
• Osimertinib